{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-109753","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.403265+00:00","generated_at":"2026-05-31T01:12:46.423707+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema targets IND for KAT6 drug OP-3136 in Q4 2024; Phase 1/2 starts 2025","bullets":["Non-clinical data for OP-3136 (KAT6 inhibitor) to be presented at ENA symposium Oct 23-25, 2024.","IND submission for OP-3136 anticipated in Q4 2024.","Phase 1/2 clinical study for OP-3136 expected to begin in 2025.","Potential Phase 3 trial OPERA-02 (palazestrant + ribociclib) initiation planned for 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-109753","json":"https://secwatch.observer/filing/0000950170-24-109753.json","markdown":"https://secwatch.observer/filing/0000950170-24-109753.md","text":"https://secwatch.observer/filing/0000950170-24-109753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024109753/0000950170-24-109753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024109753/olma-20240927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:12:46.423707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}